BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30195467)

  • 1. Hiding in Plain Sight: Soluble Immunomodulatory Receptors.
    Dahal LN; Schwarz H; Ward FJ
    Trends Immunol; 2018 Oct; 39(10):771-774. PubMed ID: 30195467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors: outstanding efficacy but at what cost?
    Klastersky JA
    Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-CTLA-4 therapy for malignant mesothelioma.
    Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
    Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 9. Part II: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
    Hahn AW; Gill DM; Pal SK; Agarwal N
    Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basics of PD-1 in self-tolerance, infection, and cancer immunity.
    Chikuma S
    Int J Clin Oncol; 2016 Jun; 21(3):448-55. PubMed ID: 26864303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
    Iivanainen S; Koivunen JP
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
    Skafi N; Fayyad-Kazan M; Badran B
    Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers associated with checkpoint inhibitors.
    Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
    Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy of patients with HIV infection.
    Gonzalez-Cao M; Martinez-Picado J; Karachaliou N; Rosell R; Meyerhans A
    Clin Transl Oncol; 2019 Jun; 21(6):713-720. PubMed ID: 30446984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.